Delayed Imatinib Treatment for Acute Spinal Cord Injury: Functional Recovery and Serum Biomarkers

Journal of Neurotrauma

Volumn 32, Issue 21, 2015, Pages 1645-1657

  Kjell, Jacob ^a   Finn, Anja ^a   Hao, Jingxia ^a   Wellfelt, Katrin ^a   Josephson, Anna ^a   Svensson, Camilla I ^a   Wiesenfeld Hallin, Zsuzsanna ^a   Eriksson, Ulf ^a   Abrams, Mathew ^a   Olson, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

bladder function; chemokines; cytokines; glivec; locomotor function

Indexed keywords

BIOLOGICAL MARKER; CHEMOATTRACTANT; CHEMOKINE; CYTOKINE; IMATINIB; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE INHIBITOR;

ACUTE SPINAL CORD INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOFLUORESCENCE; BLADDER; BLADDER FUNCTION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; HINDLIMB; HYPERSENSITIVITY; KERATINOCYTE; LOCOMOTION; LYMPHOID ORGAN; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; ONCOGENE; SPINAL CORD INJURY; ANIMAL; BLOOD; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; FEMALE; PHYSIOLOGY; RAT; SPINAL CORD INJURIES; SPRAGUE DAWLEY RAT; TIME FACTOR;

ANIMALS; BIOMARKERS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; IMATINIB MESYLATE; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; SPINAL CORD INJURIES; TIME FACTORS;

EID: 84946073555     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2014.3863     Document Type: Article

References (69)

1. (2013). Spinal cord injury facts and figures at a glance. J. Spinal Cord Med. 36, 715-716.
2. Sayer, F.T., Kronvall, E., Nilsson, O.G. (2006). Methylprednisolone treatment in acute spinal cord injury: the myth challenged through a structured analysis of published literature. Spine J. 6, 335-343.
3. Steeves, J., Blight, A. (2012). Spinal cord injury clinical trials translational process, review of past and proposed acute trials with reference to recommended trial guidelines. Handb. Clin. Neurol. 109, 386-397.
4. Ashburn, T.T., Thor, K.B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673-683.
5. Abrams, M.B., Nilsson, I., Lewandowski, S.A., Kjell, J., Codeluppi, S., Olson, L., Eriksson, U. (2012). Imatinib enhances functional outcome after spinal cord injury. PLoS ONE 7, e38760.
6. Fabian, M.A., Biggs, W.H., Treiber, D.K., Atteridge, C.E., Azimioara, M.D., Benedetti, M.G., Carter, T.A., Ciceri, P., Edeen, P.T., Floyd, M., Ford, J.M., Galvin, M., Gerlach, J.L., Grotzfeld, R.M., Herrgard, S., Insko, D.E., Insko, M.A., Lai, A.G., Lélias, J.-M., Mehta, S.A., Milanov, Z.V., Velasco, A.M., Wodicka, L.M., Patel, H.K., Zarrinkar, P.P., Lockhart, D.J. (2005). A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336.
7. Siehl, J., Thiel, E. (2007). C-kit, GIST, and imatinib. Recent Results Cancer Res. 176, 145-151.
8. Cools, J., DeAngelo, D.J., Gotlib, J., Stover, E.H., Legare, R.D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J.D., Cross, N.C.P., Tefferi, A., Malone, J., Alam, R., Schrier, S.L., Schmid, J., Rose, M., Vandenberghe, P., Verhoef, G., Boogaerts, M., Wlodarska, I., Kantarjian, H., Marynen, P., Coutre, S.E., Stone, R., Gilliland, D.G. (2003). A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214.
9. Daniels, C.E., Wilkes, M.C., Edens, M., Kottom, T.J., Murphy, S.J., Limper, A.H., Leof, E.B. (2004). Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 114, 1308-1316.
10. Pardanani, A., Elliott, M., Reeder, T., Li, C.Y., Baxter, E.J. (2003). Imatinib for systemic mast-cell disease. Lancet. 362, 535-536.
11. Seggewiss, R., Loré, K., Greiner, E., Magnusson, M.K., Price, D.A., Douek, D.C., Dunbar, C.E., Wiestner, A. (2005). Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dosedependent manner. Blood 105, 2473-2479.
12. Dewar, A.L., Cambareri, A.C., Zannettino, A.C.W., Miller, B.L., Doherty, K.V., Hughes, T.P., Lyons, A.B. (2005). Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105, 3127-3132.
13. Balachandran, V.P., Cavnar, M.J., Zeng, S., Bamboat, Z.M., Ocuin, L.M., Obaid, H., Sorenson, E.C., Popow, R., Ariyan, C., Rossi, F., Besmer, P., Guo, T., Antonescu, C.R., Taguchi, T., Yuan, J., Wolchok, J.D., Allison, J.P., DeMatteo, R.P. (2011). Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 17, 1094-1100.
14. Su, E.J., Fredriksson, L., Geyer, M., Folestad, E., Cale, J.,rae, J., Gao, Y., Pietras, K., Mann, K., Yepes, M., Strickland, D.K., Betsholtz, C., Eriksson, U., Lawrence, D.A. (2008). Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat. Med. 14, 731-737.
15. Sharp, K.G., Yee, K.M., Steward, O. (2014). A re-assessment of treatment with a tyrosine kinase inhibitor (imatinib) on tissue sparing and functional recovery after spinal cord injury. Exp. Neurol. 254, 1-11
16. Abrams, M.B., Nilsson, I., Kjell, J., Lewandowski, S., Codeluppi, S., Eriksson, U., Olson, L. (2014). Response to the report, "A reassessment of treatment with a tyrosine kinase inhibitor (imatinib) on tissue sparing and functional recovery after spinal cord injury" by Sharp et al. Exp. Neurol. 257, 182-185.
17. Adzemovic, M.Z., Zeitelhofer, M., Eriksson, U., Olsson, T., Nilsson, I. (2013). Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PLoS One 8, e56586.
18. Deng, J., Zhang, Y., Wang, L., Zhao, J., Song, B., Li, L. (2013). The effects of Glivec on the urinary bladder excitation of rats with suprasacral or sacral spinal cord transection. J. Surg. Res. 183, 598-605.
19. Krishna, V.,rews, H., Varma, A., Mintzer, J., Kindy, M.S., Guest, J. (2014). Spinal cord injury: how can we improve the classification and quantification of its severity and prognosis? J. Neurotrauma 31, 215-227.
20. Kwon, B.K., Okon, E.B., Tsai, E., Beattie, M.S., Bresnahan, J.C., Magnuson, D.K., Reier, P.J., McTigue, D.M., Popovich, P.G., Blight, A.R., Oudega, M., Guest, J.D., Weaver, L.C., Fehlings, M.G., Tetzlaff, W. (2010). A grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury. J. Neurotrauma 28, 1525-1543.
21. Dvorak, M.F., Noonan, V.K., Fallah, N., Fisher, C.G., Rivers, C.S., Ahn, H., Tsai, E.C., Linassi, A.G., Christie, S.D., Attabib, N., Hurlbert, R.J., Fourney, D.R., Johnson, M.G., Fehlings, M.G., Drew, B., Bailey, C.S., Paquet, J., Parent, S., Townson, A., Ho, C., Craven, B.C., Gagnon, D., Tsui, D., Fox, R., Mac-Thiong, J.-M., Kwon, B.K. (2014). Minimizing errors in acute traumatic spinal cord injury trials by acknowledging the heterogeneity of spinal cord anatomy and injury severity: an observational Canadian cohort analysis. J. Neurotrauma 31, 1540-1547.
22. Filli, L., Schwab, M.E. (2012). The rocky road to translation in spinal cord repair. Ann. Neurol. 72, 491-501.
23. Hofstetter, C.P., Holmström, N.A.V., Lilja, J.A., Schweinhardt, P., Hao, J., Spenger, C., Wiesenfeld-Hallin, Z., Kurpad, S.N., Frisén, J., Olson, L. (2005). Allodynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome. Nat. Neurosci. 8, 346-353.
24. Li, X., Li, G., Xu, H., Tang, X., Gao, Y., Xu, C., Liu, S., Xie, J., Tu, G., Peng, H., Qiu, S., Liang, S. (2012). Effects of anti-rVEGF on the expression of VEGF receptor-2 and P2X(2/3) receptors of the spinal dorsal horn in neuropathic pain rats. Brain Res. Bull. 87, 227-233.
25. Gwak, Y.S., Nam, T.S., Paik, K.S., Hulsebosch, C.E., Leem, J.W. (2003). Attenuation of mechanical hyperalgesia following spinal cord injury by administration of antibodies to nerve growth factor in the rat. Neurosci. Lett. 336, 117-120.
26. Lammertse, D., Tuszynski, M.H., Steeves, J.D., Curt, A. (2007). Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design. Spinal Cord 45, 232-242.
27. Steeves, J.D., Lammertse, D., Curt, A., Fawcett, J.W., Tuszynski, M.H., Ditunno, J.F., Ellaway, P.H., Fehlings, M.G., Guest, J.D., Kleitman, N., Bartlett, P.F., Blight, A.R., Dietz, V., Dobkin, B.H., Grossman, R., Short, D., Nakamura, M., Coleman, W.P., Gaviria, M., Privat, A., International Campaign for Cures of Spinal Cord Injury Paralysis. (2007). Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 45, 206-221.
28. Haouala, A.,Widmer, N., Duchosal, M.A., Montemurro, M., Buclin, T., Decosterd, L.A. (2011). Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117, e75-e87.
29. Gurney, H., Wong, M., Balleine, R.L., Rivory, L.P., McLachlan, A.J., Hoskins, J.M., Wilcken, N., Clarke, C.L., Mann, G.J., Collins, M., Delforce, S.-E., Lynch, K., Schran, H. (2007). Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin. Pharmacol. Ther. 82, 33-40.
30. Evans, W.E., McLeod, H.L. (2003). Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549.
31. Kwon, B.K., Stammers, A.M.T., Belanger, L.M., Bernardo, A., Chan, D., Bishop, C.M., Slobogean, G.P., Zhang, H., Umedaly, H., Giffin, M., Street, J., Boyd, M.C., Paquette, S.J., Fisher, C.G., Dvorak, M.F. (2010). Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J. Neurotrauma 27, 669-682.
32. Hayashi, Y., Nakamae, H., Katayama, T., Nakane, T., Koh, H., Nakamae, M., Hirose, A., Hagihara, K., Terada, Y., Nakao, Y., Hino, M. (2012). Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma 53, 1084-1089.
33. Lubieniecka, J.M., Streijger, F., Lee, J.H.T., Stoynov, N., Liu, J., Mottus, R., Pfeifer, T., Kwon, B.K., Coorssen, J.R., Foster, L.J., Grigliatti, T.A., Tetzlaff, W. (2011). Biomarkers for severity of spinal cord injury in the cerebrospinal fluid of rats. PLoS One 6, e19247.
34. Stammers, A.T., Liu, J., Kwon, B.K. (2012). Expression of inflammatory cytokines following acute spinal cord injury in a rodent model. J. Neurosci. Res. 90, 782-790.
35. Gruner, J.A. (1992). A monitored contusion model of spinal cord injury in the rat. J. Neurotrauma 9, 123-128.
36. Kjell, J., Josephson, A., Abrams, M.B., Sandor, K., Svensson, C.I. (2013). Rat substrains differ in the magnitude of spontaneous locomotor recovery and in the development of mechanical hypersensitivity after experimental spinal cord injury. J. Neurotrauma. 30, 1805-1811.
37. Petain, A., Kattygnarath, D., Azard, J., Chatelut, E. (2008). Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin. Cancer Res. 14, 7102-7109.
38. Hoshino-Yoshino, A., Kato, M., Nakano, K., Ishigai, M., Kudo, T., Ito, K. (2011). Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics. Drug Metab. Pharmacokinet. 26, 612-620.
39. Basso, D.M., Beattie, M.S., Bresnahan, J.C. (1995). A sensitive and reliable locomotor rating scale for open field testing in rats. J. Neurotrauma 12, 1-21.
40. Lankhorst, A.J., Verzijl, M.R., Hamers, F.P.T. (1999). Experimental spinal cord contusion injury: comparison of different outcome parameters. Neurosci. Res. Commun. 24, 135-148.
41. Chaplan, S.R., Bach, F.W., Pogrel, J.W., Chung, J.M., Yaksh, T.L. (1994). Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53, 55-63.
42. Scheff, S.W., Saucier, D.A., Cain, M.E. (2002). A statistical method for analyzing rating scale data: the BBB locomotor score. J. Neurotrauma 19, 1251-1260.
43. Matsui, T., Akahoshi, T., Namai, R. (2001). Selective recruitment of CCR6-expressing cells by increased production of MIP-3a in rheumatoid arthritis. Clin. Exper. Immunol. 125, 155-161.
44. Becker, L.C. (2005). Yin and yang of MCP-1. Circ. Res. 96, 812-814.
45. Blomster, L.V., Brennan, F.H., Lao, H.W., Harle, D.W. (2013). Mobilisation of the splenic monocyte reservoir and peripheral CX 3 CR1 deficiency adversely affects recovery from spinal cord injury. Exper. Neurol. 247:226-240.
46. Brunk, U.T., Terman, A. (2002). Lipofuscin: mechanisms of agerelated accumulation and influence on cell function. Free Radic. Biol. Med. 33, 611-619.
47. Greenhalgh, A.D., David, S. (2014). Differences in the phagocytic response of microglia and peripheral macrophages after spinal cord injury and its effects on cell death. J. Neurosci. 34, 6316-6322.
48. Donnelly, D.J., Longbrake, E.E., Shawler, T.M. (2011). Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo/iNOS+ macrophages. J. Neurosci. 31, 9910-9922.
49. Williams, P.R., Marincu, B.-N., Sorbara, C.D., Mahler, C.F., Schumacher, A.M., Griesbeck, O., Kerschensteiner, M., Misgeld, T. (2014). A recoverable state of axon injury persists for hours after spinal cord contusion in vivo. Nat Commun 5, 5683.
50. Lou, J., Lenke, L.G., Ludwig, F.J., O'Brien, M.F. (1998). Apoptosis as a mechanism of neuronal cell death following acute experimental spinal cord injury. Spinal Cord 36, 683-690.
51. Crowe, M.J., Bresnahan, J.C., Shuman, S.L., Masters, J.N., Beattie, M.S. (1997). Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat. Med. 3, 73-76.
52. Shuman, S.L., Bresnahan, J.C., Beattie, M.S. (1997). Apoptosis of microglia and oligodendrocytes after spinal cord contusion in rats. J. Neurosci. Res. 50, 798-808.
53. Emery, E., Aldana, P., Bunge, M.B., Puckett, W., Srinivasan, A., Keane, R.W., Bethea, J., Levi, A.D. (1998). Apoptosis after traumatic human spinal cord injury. J. Neurosurg. 89, 911-920.
54. Peng, B. (2004). Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 22, 935-942.
55. Paulson, T.A.W., Goosey-Tolfrey, V.L., Lenton, J.P., Leicht, C.A., Bishop, N.C. (2013). Spinal cord injury level and the circulating cytokine response to strenuous exercise. Med. Sci. Sports. Exerc. 45, 1649-1655.
56. Schwab, J.M., Zhang, Y., Kopp, M.A., Brommer, B., Popovich, P.G. (2014). The paradox of chronic neuroinflammation, systemic immune suppression, autoimmunity after traumatic chronic spinal cord injury. Exp. Neurol. 258, 121-129.
57. Gris, D., Hamilton, E.F., Weaver, L.C. (2008). The systemic inflammatory response after spinal cord injury damages lungs and kidneys. Exp. Neurol. 211, 259-270.
58. Sauerbeck, A.D., Laws, J.L., Bandaru, V.V.R., Popovich, P.G., Haughey, N.J., McTigue, D.M. (2015). Spinal cord injury causes chronic liver pathology in rats. J. Neurotrauma 32, 159-169.
59. Adzemovic, M.V., Zeitelhofer, M., Eriksson, U., Olsson, T., Nilsson, I. (2013). Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PLoS One 8, e56586.
60. Kobayashi, S., Kimura, F., Ikeda, T., Osawa, Y., Torikai, H., Kobayashi, A., Sato, K., Motoyoshi, K. (2009). BCR-ABL promotes neutrophil differentiation in the chronic phase of chronic myeloid leukemia by downregulating c-Jun expression. Leukemia 23, 1622-1627.
61. Veneri, D., Franchini, M., Bonora, E. (2005). Imatinib and regression of type 2 diabetes. N. Engl. J. Med. 352, 1049-1050.
62. Paniagua, R.T., Sharpe, O., Ho, P.P., Chan, S.M., Chang, A., Higgins, J.P., Tomooka, B.H., Thomas, F.M., Song, J.J., Goodman, S.B., Lee, D.M., Genovese, M.C., Utz, P.J., Steinman, L., Robinson, W.H. (2006). Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116, 2633-2642.
63. Mughal, T.I., Schrieber, A. (2010). Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics 4, 315-323.
64. Widakowich, C., de Castro, G., De Azambuja, E. (2007). Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist. 12, 1443-1455.
65. Tsao, A.S., Kantarjian, H., Cortes, J., O'Brien, S., Talpaz, M. (2003). Imatinib mesylate causes hypopigmentation in the skin. Cancer. 98, 2483-2487.
66. Kigerl, K.A., Gensel, J.C., Ankeny, D.P., Alexander, J.K., Donnelly, D.J., Popovich, P.G. (2009). Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci. 29, 13435-13444.
67. Rapalino, O., Lazarov-Spiegler, O., Agranov, E., Velan, G.J., Yoles, E., Fraidakis, M., Solomon, A., Gepstein, R., Katz, A., Belkin, M., Hadani, M., Schwartz, M. (1998). Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat. Med. 4, 814-821.
68. David, S., Kroner, A. (2011). Repertoire of microglial and macrophage responses after spinal cord injury. Nat. Rev. Neurosci. 12, 388-399.
69. Silver, J., Schwab, M.E., Popovich, P.G. (2014). Central nervous system regenerative Failure: role of oligodendrocytes, astrocytes, and microglia. Cold Spring Harb. Perspect. Biol. 7, a020602.